Literature DB >> 20382191

Sustained release of vancomycin from polyurethane scaffolds inhibits infection of bone wounds in a rat femoral segmental defect model.

Bing Li1, Kate V Brown, Joseph C Wenke, Scott A Guelcher.   

Abstract

Infection is a common complication in open fractures that compromises the healing of bone and can result in loss of limb or life. Currently, the clinical standard of care for treating contaminated open fractures comprises a staged approach, wherein the wound is first treated with non-biodegradable antibiotic-laden poly(methyl methacrylate) (PMMA) beads to control the infection followed by bone grafting. Considering that tissue regeneration is associated with new blood vessel formation, which takes up to 6 weeks in segmental defects, a biodegradable bone graft with sustained release of an antibiotic is desired to prevent the implant from becoming infected, thus allowing the processes of both vascularization and new bone formation to occur unimpeded. In the present study, we utilized biodegradable porous polyurethane (PUR) scaffolds as the delivery vehicle for vancomycin. Hydrophobic vancomycin free base (V-FB) was obtained by precipitating the hydrophilic vancomycin hydrochloride (V-HCl) at pH 8. The decreased solubility of V-FB resulted in an extended vancomycin release profile in vitro, as evidenced by the fact that active vancomycin was released for up to 8 weeks at concentrations well above both the minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC). Using PUR prepared from lysine triisocyanate (LTI) (PUR(LTI)), the extended in vitro release profile observed for V-FB translated to improved infection control in vivo compared to V-HCl in a contaminated critical-sized fat femoral segmental defect. The performance of PUR(LTI)/V-FB was comparable to PMMA/V-HCl beads in vivo. However, compared with PMMA, PUR is a biodegradable system which does not require the extra surgical removal step in clinical use. These results suggest that PUR scaffolds incorporating V-FB could be a potential clinical therapy for treatment of infected bone defects. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20382191     DOI: 10.1016/j.jconrel.2010.04.002

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  42 in total

Review 1.  Infection in conflict wounded.

Authors:  W G P Eardley; K V Brown; T J Bonner; A D Green; J C Clasper
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-01-27       Impact factor: 6.237

Review 2.  Technologies for controlled, local delivery of siRNA.

Authors:  Samantha M Sarett; Christopher E Nelson; Craig L Duvall
Journal:  J Control Release       Date:  2015-11-28       Impact factor: 9.776

3.  Sustained local delivery of siRNA from an injectable scaffold.

Authors:  Christopher E Nelson; Mukesh K Gupta; Elizabeth J Adolph; Joshua M Shannon; Scott A Guelcher; Craig L Duvall
Journal:  Biomaterials       Date:  2011-11-05       Impact factor: 12.479

Review 4.  Injectable foams for regenerative medicine.

Authors:  Edna M Prieto; Jonathan M Page; Andrew J Harmata; Scott A Guelcher
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2013-10-11

Review 5.  Infected animal models for tissue engineering.

Authors:  Alexander M Tatara; Sarita R Shah; Carissa E Livingston; Antonios G Mikos
Journal:  Methods       Date:  2015-04-02       Impact factor: 3.608

6.  Controlled release of IGF-1 and HGF from a biodegradable polyurethane scaffold.

Authors:  Devin M Nelson; Priya R Baraniak; Zuwei Ma; Jianjun Guan; N Scott Mason; William R Wagner
Journal:  Pharm Res       Date:  2011-02-23       Impact factor: 4.200

Review 7.  Therapeutics and delivery vehicles for local treatment of osteomyelitis.

Authors:  Leah H Cobb; Emily M McCabe; Lauren B Priddy
Journal:  J Orthop Res       Date:  2020-04-21       Impact factor: 3.494

8.  Vancomycin-bearing synthetic bone graft delivers rhBMP-2 and promotes healing of critical rat femoral segmental defects.

Authors:  Jordan D Skelly; Jeffrey Lange; Tera M Filion; Xinning Li; David C Ayers; Jie Song
Journal:  Clin Orthop Relat Res       Date:  2014-08-07       Impact factor: 4.176

9.  pHEMA-nHA encapsulation and delivery of vancomycin and rhBMP-2 enhances its role as a bone graft substitute.

Authors:  Xinning Li; Jianwen Xu; Tera M Filion; David C Ayers; Jie Song
Journal:  Clin Orthop Relat Res       Date:  2013-08       Impact factor: 4.176

10.  Evaluation of Silver Ion-Releasing Scaffolds in a 3D Coculture System of MRSA and Human Adipose-Derived Stem Cells for Their Potential Use in Treatment or Prevention of Osteomyelitis.

Authors:  Mahsa Mohiti-Asli; Casey Molina; Thamonwan Diteepeng; Behnam Pourdeyhimi; Elizabeth G Loboa
Journal:  Tissue Eng Part A       Date:  2016-10-25       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.